Clinical and economic analysis of the use of apixaban for the treatment of venous thromboembolic events by O. V. Shatalova

Subjects: “…pharmacoeconomics…”
Get full text

Outcomes research and drug development by Sandeep Duttagupta

Subjects: Get full text

Evaluating the Use of Dalbavancin for Off-Label Indications by Katherine Taylor, John Williamson, Vera Luther, Tyler Stone, James Johnson, Zachary Gruss, Courtney Russ-Friedman, Chris Ohl, James Beardsley

Subjects: Get full text

Drug costs in context: assessing drug costs in cost-of-illness analyses by T Joseph Mattingly II, Shannon Weathers

Subjects: Get full text

Clinical-economic analysis of valproate microsphere form in focal epilepsy in adults (real world evidences) by D. Yu. Belousov, L. N. Bistritskaya, E. V. Afanasyeva

Subjects: Get full text

Evaluación de los costes asociados a la enfermedad de pacientes con linfoma cutáneo de células T en España: análisis en función del estadio clínico (estudio MICADOS) by B. Navarro Matilla, P.L. Ortiz Romero, R.M. Pujol Vallverdú, A. Combalia Escudero, I. Zapata Paz, E. González Barca, C. Muniesa Montserrat, M. Morillo Andújar, A. Pérez Ferriols, C. Román Curto, R. Fernández de Misa Cabrera, M. Hospital Gil, A. Marín Niebla, P.J. Rios Rull, F. de la Cruz Vicente, R.M. Izu Belloso, A. Martín García-Sancho, M.E. Parera Amer, R. Córdoba Mascuñano, M.D. Ramón Quiles, A. Saus Carreres, R. del Campo García, S. Machan, P. Viguera Ester, J. Blanco Garnelo

Subjects: Get full text

Cost Variation Analysis of Branded Generics Used for Initial Treatment of Type 2 Diabetes, Hypertension and Dyslipidemia in India by IJASUL HAQUE M

Subjects: “…Pharmacoeconomics…”
Get full text

Impact of the genomic signature of 70-genes for breast cancer in the public system and in supplementary health care in a country of medium socioeconomic development by Fabio Postiglione Mansani, Leonardo Ribeiro Soares, Ruffo de Freitas Junior

Subjects: Get full text

Factors Impacting Pharmaceutical Prices and Affordability: Narrative Review by Kah Seng Lee, Yaman Walid Kassab, Nur Akmar Taha, Zainol Akbar Zainal

Subjects: Get full text

Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review by Abdalla Aly, Sarah Ronnebaum, Dipen Patel, Yunes Doleh, Fernando Benavente

Subjects: Get full text

Prevention and treatment of neutropenia in routine clinical practice. How to improve the quality of cancer care and reduce treatment costs? by G. A. Gromova

Subjects: Get full text

Laryngeal cancer treatment cost-effectiveness by Magdalena Ściesińska, Anna Sinkiewicz, Mirosława Kowalkowska, Grzegorz Grześk

Subjects: Get full text

PHARMACOECONOMIC ASPECTS OF TREATMENT WITH THE INHIBITORS OF TUMOR NECROSIS FACTOR OF THE CHRONIC UVEITIS REFRACTORY TO THE BASIC THERAPY (INCLUDING AN ASSOCIATED WITH JUVENILE IDIOPATHIC ARTHRITIS) by A.V. Rudakova

“…Conclusions. The realized pharmacoeconomic analysis suggests the feasibility of adalimumab treatment of chronic uveitis refractory to routine therapy. …”
Get full text

PHARMACOECONOMIC ASPECTS OF TREATMENT WITH THE INHIBITORS OF TUMOR NECROSIS FACTOR OF THE CHRONIC UVEITIS REFRACTORY TO THE BASIC THERAPY (INCLUDING AN ASSOCIATED WITH JUVENILE IDIOPATHIC ARTHRITIS) by A.V. Rudakova

“…Conclusions. The realized pharmacoeconomic analysis suggests the feasibility of adalimumab treatment of chronic uveitis refractory to routine therapy. …”
Get full text

Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis by Christophe Sapin, Ann Hartry, Siddhesh A Kamat, Maud Beillat, Ross A Baker, Anna Eramo

Get full text

PERAMPANEL EFFECTIVENESS IN THE TREATMENT OF REFRACTERY PARTIAL ONSET EPILEPSY WITH OR WITHOUT SECONDARY GENERALIZATION: PHARMACOECONOMIC ANALYSIS FOR THE RUSSIAN FEDERATION HEALTH CARE SYSTEM by N. K. Mazina, I. V. Sheshunov, P. V. Мazin, Yu. V. Kislitsin, E. M. Markova

Subjects: Get full text

PROTEASE INHIBITOR NARLAPREVIR IN THERAPY OF HEPATITIS C VIRUS GENOTYPE 1 INFECTION IN TREATMENT-NAÏVE PATIENTS WITHOUT CIRRHOSIS: PHARMACOECONOMIC EVALUATION by A. V. Rudakova, D. A. Gusev, A. N. Uskov, L. N. Konovalova, Yu. V. Lobzin

Get full text

Analysis of the pharmacoeconomic effectiveness of the tyrosine kinase inhibitors therapy in patients with chronic myeloid leukemia in a Single Hematology Center in Plovdiv, Bulgaria by Veselina Goranova-Marinova, Daniela Grekova-Kafalova, Kalina Andreevska, Vania Georgieva, Yana Gvozdeva, Margarita Kassarova, Zhanet Grudeva-Popova, Evelina Gavazova, Valentina Petkova

“…Results: The sensitivity analyzes of all pharmacoeconomic models showed the robustness and reliability of the obtained results. …”
Get full text

Pharmacoeconomic analysis of trastuzumab emtanzine comparing to lapatinib + capecitabine in pa-tients with HER2+ breast cancer and central nervous system metastases by A. S. Kolbin, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, D. R. Naskhletashvili

Get full text

Pharmacoeconomic analysis of fixed-duration targeted therapy regimens for chronic lymphocytic leukemia compared with therapy used until progression or intolerable toxicity by A. R. Kasimova, A. S. Kolbin, M. A. Proskurin, Yu. E. Balykina

Subjects: Get full text